Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China
about
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsIDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in gliomaATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype.MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma.HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation.Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance.Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtypeMethylation associated genes contribute to the favorable prognosis of gliomas with isocitrate dehydrogenase 1 mutation.CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO)IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.KIF23 is an independent prognostic biomarker in glioma, transcriptionally regulated by TCF-4.IDH-1R132H mutation status in diffuse glioma patients: implications for classificationMolecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas.Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.Lessons from next-generation sequencing analysis in hematological malignancies.Tumor location and patient age predict biological signatures of high-grade gliomas.Expression signatures of DNA repair genes correlate with survival prognosis of astrocytoma patients.Evolving Molecular Genetics of Glioblastoma.Association of The IDH1 C.395G>A (R132H) Mutation with Histological Type in Malay Brain TumorsC-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma.Clinicopathological features and molecular analysis of primary glioblastomas in Moroccan patients.Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin?Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomasIDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age.Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China.Genomic and Molecular Characterization of Brain Tumors in Asian and Non-Asian Patients of Los Angeles: A Single Institution Analysis.Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.PD-1 related transcriptome profile and clinical outcome in diffuse gliomas.Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis.Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis.
P2860
Q26795767-FB5D23FE-E4AE-45F7-9B9F-2B52C3FBC39FQ26995506-2A8CCD4B-E451-4D37-AD02-69E4C705F194Q33757037-D130AAF3-BC60-4B00-9A7E-082A1610FC62Q34313824-FD78049F-110B-4A94-A4FB-C08B5CA2D9CBQ34450679-505AE2D7-2A63-4E9B-8922-EA8184BDA95CQ35203538-40AF7D01-E004-4E82-8737-77AC76A5D9F8Q35610772-8A3AD890-362D-424E-903A-A9ACF3482749Q35675684-5BE51E8A-EB0F-419E-BF96-EFB357EBCF10Q35686908-1497DD41-C56E-48C9-B2C6-41BB4488A936Q35793894-9E121E75-2959-4A95-B06E-20709B7914C0Q36249145-1E1D9253-3A6E-41BA-89A0-FCAF807828F6Q36389768-11668037-D3B6-409A-AC77-1A53CBE7C471Q36500411-9745C95E-F513-42EB-ACFC-9BFD3CE8BAD0Q36557547-864A69C1-9C15-4093-8C47-F313207C491BQ36705913-E8205303-83C1-43A4-80CC-2DA3D8F77AE3Q37269393-3F15B6AA-71F8-44DB-9556-AAC884749965Q37327761-526A9588-A3D6-4D35-AEDD-9928DD53A2DAQ37477267-570AD648-4FE4-4EC7-8A21-DFF72EF9CF1DQ37564326-4B9B33F8-5658-4CCB-9984-CDB7C4EAEEA1Q37694886-CC6B2F74-2AC4-495B-BBD4-C2C2049766E8Q38123015-6D1E29A7-588E-4720-A136-639BCB3A6A8FQ38601045-8A22ABA0-40FB-445D-BC54-72978869407FQ38708860-9424309D-3161-4568-B3C3-A3AD4FC50249Q38734366-CB8819A7-CE13-441C-A468-AC896E96CA3FQ38997694-CE639E76-6183-4AF1-8454-2FD854E312C8Q39029492-2D2498C1-04F1-41AC-A12D-B9F34D71B7FDQ39068086-F5ACF539-A404-4C13-B4FA-29902292066DQ39441334-6DB1A11A-E9D2-4FB9-A1AC-5FC82B7E4F18Q39937053-4522C429-4B09-4DB4-927F-C519AB65705AQ42096951-BC2673A6-9C4F-4AFB-BEB0-88E54D49CD81Q42777737-730A768A-EE87-4959-A281-82165A793839Q44293216-A2A9BB21-6A28-43BE-835F-B82CFA174B13Q45819845-7CE0FD87-ED6E-4B78-B711-3DBA0D1944F6Q46020447-24455DE4-6FA7-457D-A924-3364BAD47E8EQ46830032-FC170680-DB37-4FA2-9A7F-C93545A75D05Q47199921-D652A79F-C983-4847-B8F7-A79EB9568A07Q47861348-38C4E2F0-8293-48E1-A31C-0CB304272C03Q47887297-639426FB-8DC0-4536-A118-08439092FB28Q47957409-152D0D02-5D5D-427F-B6C8-EB261715010EQ48014113-6DD88B47-B409-4276-82F4-1FD0B30F273F
P2860
Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Correlation of IDH1 mutation w ...... ort of 118 patients from China
@ast
Correlation of IDH1 mutation w ...... ort of 118 patients from China
@en
Correlation of IDH1 mutation w ...... ort of 118 patients from China
@nl
type
label
Correlation of IDH1 mutation w ...... ort of 118 patients from China
@ast
Correlation of IDH1 mutation w ...... ort of 118 patients from China
@en
Correlation of IDH1 mutation w ...... ort of 118 patients from China
@nl
prefLabel
Correlation of IDH1 mutation w ...... ort of 118 patients from China
@ast
Correlation of IDH1 mutation w ...... ort of 118 patients from China
@en
Correlation of IDH1 mutation w ...... ort of 118 patients from China
@nl
P2093
P2860
P1433
P1476
Correlation of IDH1 mutation w ...... ort of 118 patients from China
@en
P2093
Chunsheng Kang
Yanwei Liu
Yongping You
Yongzhi Wang
Zhaoshi Bao
P2860
P304
P356
10.1371/JOURNAL.PONE.0030339
P407
P577
2012-01-23T00:00:00Z